ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera
ITM Isotope Technologies Munich’s radiopharma candidate reduced neuroendocrine tumor patients’ risk of progression or death by a third compared with standard therapy, according to pivotal data presented Thursday. The figure is statistically significant but is ...
ITM Isotope Technologies Munich’s radiopharma candidate reduced neuroendocrine tumor patients’ risk of progression or death by a third compared with standard therapy, according to pivotal data presented Thursday.
The figure is statistically significant but is ...
